Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-PPDS Dose Evaluation in Glaucoma/OH
NCT01481051Phase 2Completed
- Sponsor
- Mati Therapeutics
- Start
- Nov 2011
- Primary completion
- Sep 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by Mati Therapeutics. Primary endpoint: Intraocular Pressure change from baseline at 12 weeks. Started Nov 2011; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT01481051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01481051.